Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

Research & Clinical Trials
Toggle Menu

NCT01459380

Veliparib, Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study identifier: NCT01459380
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, no more than one previous chemotherapy regimen, no prior treatment with PARP inhibitor

Type of study:

Phase I study

Treatment:

Participants will be in one of two groups:

  • 28-day cycles with veliparib orally on days 1-7 and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)
  • 28-day cycles with veliparib orally daily and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)

Study sites:

Colorado
Aurora
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Contact: Susan A. Davidson 720-848-0650

Georgia
Augusta
Georgia Regents University
Contact: Sharad A. Ghamande 706-721-1663 cancer@georgiahealth.edu

Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Contact: Seiko D. Yamada 773-834-7424

Iowa
Iowa City
University of Iowa Hospitals and Clinics
Contact: Koen De Geest 800-237-1225

New York
New York
Memorial Sloan Kettering Cancer Center
Contact: Katherine M. Bell-McGuinn 212-639-7202

Ohio
Cleveland
Case Western Reserve University
Contact: Steven E. Waggoner 800-641-2422

Cleveland Clinic Foundation
Contact: Steven E. Waggoner 800-641-2422

Columbus
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Contact: David M. O'Malley 866-627-7616 osu@emergingmed.com

Mayfield Heights
Hillcrest Hospital Cancer Center
Contact: Steven E. Waggoner 800-641-2422

Oklahoma
Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Robert S. Mannel 405-271-4272 julie-traylor@ouhsc.edu
Principal Investigator: Robert S. Mannel

Pennsylvania
Philadelphia
Gynecologic Oncology Group
Contact: Lisa M. Landrum 405-271-8707 Lisa-landrum@ouhsc.edu

Rhode Island
Providence
Women and Infants Hospital
Contact: Paul A. DiSilvestro 401-274-1122

Page updated 06/08/13